@article {SCHULTZE-SEEMANN875, author = {WOLFGANG SCHULTZE-SEEMANN and HOLGER SCHULZ and BARBARA TSCHECHNE and MANUEL H{\"A}CKL}, title = {Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study}, volume = {39}, number = {2}, pages = {875--882}, year = {2019}, doi = {10.21873/anticanres.13188}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: The combination of bevacizumab (BEV) plus interferon alpha-2a (IFN) constitutes an option for first-line treatment of metastatic renal cell carcinoma. Real-world data from routine clinical practice are rare and were, therefore, collected during this non-interventional study (NIS). Patients and Methods: A total of 359 patients received at least one dose of BEV (safety set population; SAF), 354 patients had at least one post-dose effectiveness assessment and formed the full analysis set (FAS) of the final analysis. Results: Progression-free survival (10.2 months, 95\% CI=8.6-12.6) and overall response rate (27.2\%) outcomes match the results from the phase III trials AVOREN and CALGB 90206. Longer overall survival (28.7 months, 95\% CI=24.5-38.3) probably is an effect of patient characteristics and follow-up therapies. Safety findings were comparable to the results of the Phase III trials, although comprehensive severity assessments were not provided. Conclusion: Overall, efficacy and safety data from BEV plus IFN administered in routine clinical practice in an observational NIS are in line with results from the controlled phase III trials. (NCT02627144)}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/39/2/875}, eprint = {https://ar.iiarjournals.org/content/39/2/875.full.pdf}, journal = {Anticancer Research} }